Neurocrine Biosciences, Inc. Expected to Earn Q1 2025 Earnings of $1.28 Per Share (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities researchers at William Blair issued their Q1 2025 EPS estimates for Neurocrine Biosciences in a note issued to investors on Tuesday, April 23rd. William Blair analyst M. Minter expects that the company will post earnings of $1.28 per share for the quarter. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.84 per share. William Blair also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.56 EPS, Q3 2025 earnings at $1.75 EPS and Q4 2025 earnings at $1.99 EPS.

NBIX has been the topic of several other reports. Wells Fargo & Company upgraded Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $140.00 to $170.00 in a report on Wednesday. Mizuho boosted their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a research report on Thursday, February 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, April 10th. JPMorgan Chase & Co. boosted their price objective on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research note on Tuesday. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $142.38.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $135.99 on Thursday. Neurocrine Biosciences has a 12 month low of $89.04 and a 12 month high of $148.37. The stock’s 50-day moving average is $136.63 and its two-hundred day moving average is $127.85. The stock has a market cap of $13.53 billion, a PE ratio of 56.19 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.31. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. During the same quarter in the previous year, the business posted $0.88 EPS. The business’s quarterly revenue was up 25.0% on a year-over-year basis.

Institutional Investors Weigh In On Neurocrine Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. FCF Advisors LLC bought a new stake in shares of Neurocrine Biosciences in the 4th quarter worth approximately $1,157,000. Redhawk Wealth Advisors Inc. acquired a new position in shares of Neurocrine Biosciences in the 4th quarter worth $1,245,000. HealthInvest Partners AB acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter worth $1,662,000. Roman Butler Fullerton & Co. purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at $1,256,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Neurocrine Biosciences by 128.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 44,939 shares of the company’s stock valued at $5,921,000 after purchasing an additional 25,245 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total value of $725,300.00. Following the sale, the insider now owns 7,507 shares in the company, valued at $1,088,965.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Eric Benevich sold 19,818 shares of Neurocrine Biosciences stock in a transaction on Monday, April 15th. The stock was sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the transaction, the insider now directly owns 40,778 shares in the company, valued at approximately $5,438,154.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 5,000 shares of the company’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total value of $725,300.00. Following the completion of the sale, the insider now owns 7,507 shares of the company’s stock, valued at approximately $1,088,965.42. The disclosure for this sale can be found here. Insiders sold 186,994 shares of company stock valued at $25,806,409 in the last ninety days. Company insiders own 4.40% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.